Intelesens appoints new CTO
Intelesens founder and Executive Director, Professor Jim McLaughlin has been appointed Chief Technology Officer for the company, reporting to the CEO. Previously Chief Science Officer Jim now takes over this critical executive role in providing technical and scientific leadership to the Intelesens Engineering group, which includes sensor technology, hardware, software, firmware, systems and biomedical engineering disciplines. Jim's predecessor in the role, Professor John Anderson tragically died earlier this month after a 6 month illness and had provided the visionary technology leadership which helped develop Intelesens’s range of revolutionary wearable, wireless health monitors. Jim had worked for more than 27 years with John both within the company and at the University of Ulster and will continue the drive for technological excellence started by John.
Jim is a distinguished international physicist and was recently honoured for his services to research and economic development in Northern Ireland, receiving an OBE. He is also currently the Director of the Engineering Research Institute (ERI) and Director of NIBEC at the University of Ulster’s Jordanstown campus near Belfast. With over three hundred publications and numerous successful patents, Professor McLaughlin has built an outstanding international reputation in the area of sensor and nano-based technologies and is a Fellow of the Institute of Physics.
Jim has played an active role in setting up a range of Connected Health groups in the UK including the European Connected Health Campus which he chaired for a two year period and the Connected Health Innovation Centre of which he is currently the principle investigator. In these roles Jim has developed an invaluable set of relationships with Companies, Healthcare Organisations, Clinicians and Technologists in the global Connected Healthcare space. As Intelesens moves this year from its product development phase into market deployment, Professor McLaughlin's broad perspective of both global healthcare needs and emerging technology solutions provides a huge opportunity for the company to capitalise fully in this emerging but rapidly growing market.
Intelesens CEO Michael Caulfield commented, "The loss of a great friend and colleague, John Anderson, has had a major impact on the employees of Intelesens and its many international associates. Jim's ability and willingness to step into the CTO role with immediate effect is a testimony to the strong working relationship that has existed amongst our three founders and the stunning value of the company’s rich asset of technological and scientific knowledge and experience. We are determined now to drive the company with even greater effect into its commercial phase and to build on the legacy of invention, innovation and excellence in healthcare technology left to us by Professor John Anderson."